| XLS |
|
|
|
|
|
€ million |
Jan.–June 2013 |
Jan.–June 2012 |
|
Profit after tax |
585.1 |
114.6 |
|
Depreciation/amortization/impairment losses/write-ups |
682.1 |
694.6 |
|
Changes in inventories |
–43.4 |
48.8 |
|
Changes in trade accounts receivable |
–135.4 |
72.9 |
|
Changes in trade accounts payable |
37.8 |
100.1 |
|
Changes in provisions |
2.8 |
430.1 |
|
Changes in other assets and liabilities |
–131.0 |
–271.1 |
|
Neutralization of gain/loss on disposals of assets |
–37.4 |
–26.5 |
|
Other non-cash income and expenses |
–2.3 |
2.2 |
|
Net cash flows from operating activities |
958.2 |
1,165.7 |
|
|
|
|
|
Investments in intangible assets |
–50.2 |
–49.5 |
|
Investments in property, plant and equipment |
–157.2 |
–116.9 |
|
Acquisitions |
–15.1 |
–4.1 |
|
Investments in non-current financial assets |
–7.9 |
–10.8 |
|
Disposal of non-current assets |
260.4 |
50.1 |
|
Purchase/sale of marketable securities |
– |
10.9 |
|
Changes in other financial assets |
–622.0 |
–67.6 |
|
Net cash flows from investing activities |
–592.0 |
–187.9 |
|
|
|
|
|
Dividend payments |
–112.9 |
–101.8 |
|
Profit transfers to E. Merck KG and changes in reserves |
–261.9 |
–8.5 |
|
Changes in liabilities to E. Merck KG |
171.0 |
–177.7 |
|
Repayment of bonds |
– |
–500.0 |
|
Changes in current and non-current financial liabilities |
–17.9 |
–80.0 |
|
Net cash flows from financing activities |
–221.7 |
–868.1 |
|
|
|
|
|
Changes in cash and cash equivalents |
144.5 |
109.7 |
|
Changes in cash and cash equivalents due to currency translation |
–9.8 |
4.2 |
|
Cash and cash equivalents as of January 1 |
729.7 |
937.8 |
|
Cash and cash equivalents as of June 30 |
864.4 |
1,051.7 |